MX2021008050A - Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2). - Google Patents
Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2).Info
- Publication number
- MX2021008050A MX2021008050A MX2021008050A MX2021008050A MX2021008050A MX 2021008050 A MX2021008050 A MX 2021008050A MX 2021008050 A MX2021008050 A MX 2021008050A MX 2021008050 A MX2021008050 A MX 2021008050A MX 2021008050 A MX2021008050 A MX 2021008050A
- Authority
- MX
- Mexico
- Prior art keywords
- hydroxy
- halogen
- hydrogen
- dihydropyrazolopyrazinone
- acyltranferase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000002759 monoacylglycerols Chemical class 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cyano, carboxy Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019003073 | 2019-01-11 | ||
| PCT/JP2020/000553 WO2020145369A1 (ja) | 2019-01-11 | 2020-01-10 | Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008050A true MX2021008050A (es) | 2021-08-05 |
Family
ID=71520981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008050A MX2021008050A (es) | 2019-01-11 | 2020-01-10 | Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12227509B2 (https=) |
| EP (1) | EP3909583A4 (https=) |
| JP (1) | JP7608166B2 (https=) |
| KR (1) | KR20210114001A (https=) |
| CN (2) | CN119409703A (https=) |
| AU (1) | AU2020207716A1 (https=) |
| BR (1) | BR112021012428A2 (https=) |
| CA (1) | CA3126334A1 (https=) |
| MX (1) | MX2021008050A (https=) |
| TW (1) | TWI840489B (https=) |
| WO (1) | WO2020145369A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022016394A (ja) * | 2020-07-10 | 2022-01-21 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体を含有する医薬組成物 |
| WO2023038039A1 (ja) | 2021-09-08 | 2023-03-16 | 塩野義製薬株式会社 | 抗肥満作用の関与する疾患の予防及び治療用医薬 |
| WO2026008045A1 (zh) * | 2024-07-04 | 2026-01-08 | 苏州信诺维医药科技股份有限公司 | 一种含有炔基的螺环化合物及其用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1747949A (zh) | 2002-12-20 | 2006-03-15 | 法马西亚公司 | 无环吡唑化合物 |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| US8232282B2 (en) | 2006-09-28 | 2012-07-31 | Dainippon Sumitomo Pharma Co., Ltd. | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same |
| AU2007342368A1 (en) | 2007-01-04 | 2008-07-17 | Merck & Co., Inc. | Bicyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease |
| US8389533B2 (en) | 2008-04-07 | 2013-03-05 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| US20110275647A1 (en) | 2009-02-23 | 2011-11-10 | Msd K.K. | Pyrimidin-4-(3h)-one derivatives |
| KR20100097077A (ko) | 2009-02-25 | 2010-09-02 | 주식회사 중외제약 | Ｈｓｐ90에 대한 억제 효능을 갖는 피리디논 유도체 |
| SG181857A1 (en) | 2009-12-23 | 2012-07-30 | Takeda Pharmaceutical | Fused heteroaromatic pyrrolidinones as syk inhibitors |
| JP2014051434A (ja) | 2010-12-28 | 2014-03-20 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体 |
| JP5853033B2 (ja) | 2011-03-01 | 2016-02-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な６，７−ジヒドロ−ピラゾロ［１，５−ａ］ピラジン−４−イルアミン誘導体 |
| WO2012124744A1 (ja) | 2011-03-14 | 2012-09-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| JP6042060B2 (ja) | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
| PT2573073E (pt) | 2011-09-26 | 2015-02-05 | Sanofi Sa | Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica |
| CN103012397B (zh) | 2011-09-26 | 2017-03-01 | 赛诺菲 | 吡唑并喹啉酮衍生物、其制备方法及其治疗用途 |
| US8791091B2 (en) | 2011-12-02 | 2014-07-29 | Bristol-Myers Squibb Company | Aryl dihydropyridinone and piperidinone MGAT2 inhibitors |
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| AR089771A1 (es) | 2012-01-31 | 2014-09-17 | Lilly Co Eli | Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 |
| JP5852269B2 (ja) | 2012-01-31 | 2016-02-03 | イーライ リリー アンド カンパニー | Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体 |
| US9394297B2 (en) | 2012-02-28 | 2016-07-19 | Amgen Inc. | Amides as pim inhibitors |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| JP2014005245A (ja) | 2012-06-26 | 2014-01-16 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン誘導体を含有する医薬組成物 |
| JP2014009165A (ja) | 2012-06-27 | 2014-01-20 | Dainippon Sumitomo Pharma Co Ltd | 二環性ピリミジン化合物 |
| EP2903985A1 (en) | 2012-10-03 | 2015-08-12 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
| MX2015005739A (es) | 2012-11-06 | 2015-09-16 | Lilly Co Eli | Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2. |
| WO2014133134A1 (ja) | 2013-02-28 | 2014-09-04 | 味の素株式会社 | 新規テトラヒドロピリドピリミジノン誘導体 |
| CA2907532A1 (en) | 2013-03-25 | 2014-10-02 | Sanofi | Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) |
| CN104109160B (zh) | 2013-04-17 | 2017-12-15 | 上海翰森生物医药科技有限公司 | 吡咯并n杂环类化合物及其制备方法和医药用途 |
| SG11201509070YA (en) | 2013-05-29 | 2015-12-30 | Bristol Myers Squibb Co | Dihydropyridinone mgat2 inhibitors |
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| WO2015112465A1 (en) | 2014-01-24 | 2015-07-30 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives as mgat2 inhibitors |
| EP3097095A1 (en) | 2014-01-24 | 2016-11-30 | AbbVie Inc. | Furo-3-carboxamide derivatives and methods of use |
| JP6513075B2 (ja) | 2014-02-27 | 2019-05-15 | 国立大学法人 東京大学 | オートタキシン阻害活性を有する縮合ピラゾール誘導体 |
| JP2017078024A (ja) | 2014-02-28 | 2017-04-27 | 味の素株式会社 | 新規テトラヒドロピリドピリミジノン誘導体 |
| SMT201900256T1 (it) | 2014-03-07 | 2019-07-11 | Bristol Myers Squibb Co | Inibitori dell'mgat2 diidropiridinonici sostituiti con tetrazolone |
| SG11201607392SA (en) | 2014-03-07 | 2016-10-28 | Bristol Myers Squibb Co | Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders |
| EP3129376B1 (en) | 2014-03-27 | 2018-12-26 | Janssen Pharmaceutica NV | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo[1,5-a][1,4]diazepine derivatives as ros1 inhibitors |
| WO2015191681A2 (en) | 2014-06-11 | 2015-12-17 | Bristol-Myers Squibb Company | Substituted pyridinones as mgat2 inhibitors |
| JP2017171579A (ja) * | 2014-08-11 | 2017-09-28 | 味の素株式会社 | 新規テトラヒドロピリドピリミジノン誘導体 |
| CN107205993B (zh) | 2014-12-06 | 2021-03-09 | 细胞内治疗公司 | 有机化合物 |
| WO2016106009A1 (en) | 2014-12-22 | 2016-06-30 | Eli Lilly And Company | Erk inhibitors |
| JP2018052818A (ja) * | 2015-01-28 | 2018-04-05 | 武田薬品工業株式会社 | スルホンアミド化合物 |
| JP2016164154A (ja) | 2015-02-26 | 2016-09-08 | 塩野義製薬株式会社 | オートタキシン阻害活性を有する７位無置換縮合ピラゾール誘導体 |
| WO2017069224A1 (ja) | 2015-10-22 | 2017-04-27 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有するスピロ環誘導体 |
| US10335401B2 (en) * | 2015-12-21 | 2019-07-02 | Shionogi & Co., Ltd. | Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity |
| JP6665575B2 (ja) | 2016-02-23 | 2020-03-13 | ブラザー工業株式会社 | プログラム |
| JP2020158390A (ja) * | 2017-06-20 | 2020-10-01 | 塩野義製薬株式会社 | Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体およびそれらを含有する医薬組成物 |
| TWI782056B (zh) * | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
-
2020
- 2020-01-10 CA CA3126334A patent/CA3126334A1/en active Pending
- 2020-01-10 TW TW109100924A patent/TWI840489B/zh not_active IP Right Cessation
- 2020-01-10 BR BR112021012428-4A patent/BR112021012428A2/pt not_active Application Discontinuation
- 2020-01-10 CN CN202411241356.4A patent/CN119409703A/zh active Pending
- 2020-01-10 JP JP2020565216A patent/JP7608166B2/ja active Active
- 2020-01-10 MX MX2021008050A patent/MX2021008050A/es unknown
- 2020-01-10 US US17/422,108 patent/US12227509B2/en active Active
- 2020-01-10 CN CN202080018835.3A patent/CN113557021A/zh active Pending
- 2020-01-10 KR KR1020217023263A patent/KR20210114001A/ko not_active Withdrawn
- 2020-01-10 AU AU2020207716A patent/AU2020207716A1/en not_active Abandoned
- 2020-01-10 EP EP20739159.0A patent/EP3909583A4/en active Pending
- 2020-01-10 WO PCT/JP2020/000553 patent/WO2020145369A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20220135577A1 (en) | 2022-05-05 |
| TWI840489B (zh) | 2024-05-01 |
| JP7608166B2 (ja) | 2025-01-06 |
| EP3909583A1 (en) | 2021-11-17 |
| BR112021012428A2 (pt) | 2021-09-08 |
| KR20210114001A (ko) | 2021-09-17 |
| CA3126334A1 (en) | 2020-07-16 |
| TW202043235A (zh) | 2020-12-01 |
| WO2020145369A1 (ja) | 2020-07-16 |
| CN119409703A (zh) | 2025-02-11 |
| EP3909583A4 (en) | 2022-08-17 |
| AU2020207716A1 (en) | 2021-07-15 |
| JPWO2020145369A1 (ja) | 2021-11-25 |
| US12227509B2 (en) | 2025-02-18 |
| CN113557021A (zh) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001618A1 (es) | Un medicamento que comprende a) compuestos heterociclicos nitrogenados fusionados, moduladores de cen y cpe, y b) un compuestyo o anticuerpo con actividad antiinfluenza; y su uso para la influenza. | |
| SA520411017B1 (ar) | Mgat-2 مشتق ذو حلقة ملتحمة له نشاط مثبط لـ | |
| MX2021008050A (es) | Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2). | |
| MX2017013809A (es) | Derivados de piridona policiclica sustituida y profarmaco de los mismos. | |
| CO2021008681A2 (es) | Inhibidor de 15-pgdh | |
| GEP20247607B (en) | Nitrile-containing antiviral compounds | |
| MX2023000630A (es) | Inhibidor de rock, y método de preparacion para el mismo y uso del mismo. | |
| AR114827A1 (es) | Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida | |
| BR112021022659A2 (pt) | Compostos triarílicos para o tratamento de doenças pd-l1 | |
| CY1113813T1 (el) | Νεες ενωσεις που εχουν ανασταλτικη δραστικοτητα εναντια στον εξαρτωμενο απο το νατριο μεταφορεα | |
| MX2019001640A (es) | Composiciones farmaceuticas que contienen derivados de piridona policiclicos sustituidos y profarmacos de los mismos. | |
| CY1113352T1 (el) | Ενωση σπειρο-δακτυλιου και χρηση αυτης για ιατρικους σκοπους | |
| CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| AR058433A1 (es) | Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso | |
| CL2012002526A1 (es) | Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca. | |
| PH12017501909A1 (en) | Substituted polycyclic pyridone derivatives and prodrug thereof | |
| EA200401304A1 (ru) | Набор для ингаляции с ингаляционным порошком, содержащим тиотропий | |
| UY31674A1 (es) | Derivado heterocíclico fusionado y su uso | |
| ECSP22005485A (es) | Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos | |
| AR083060A1 (es) | Compuesto de ciclopropano y composiciones farmaceuticas que lo contienen | |
| CY1117004T1 (el) | Παραγωγο τετραϋδροϊσοκινολιν-1-ονης ή αλας εξ' αυτου | |
| DOP2021000272A (es) | Uso terapéutico de agonista trigonal de los receptores de glucagon, glp-1 y gip o conjugado de los mismos para enfermedades hepáticas | |
| PH12022551241A1 (en) | Egfr inhibitors | |
| AR114270A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmacéutico | |
| TN2009000434A1 (en) | Bicyclic coumpound and pharmaceutical use thereof |